In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Bruker, with a price target of $60.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Ryskin has given his Buy rating due to a combination of factors including Bruker’s strong confidence in their 2026 financial framework, which anticipates flat to low single-digit organic revenue growth, a 300 basis points margin expansion, and double-digit EPS growth. The company expects headwinds in key end markets to diminish and has observed encouraging trends in recent quarters, particularly in the pharmaceutical sector where R&D activity is picking up.
Additionally, Bruker’s margin improvement initiatives, which include significant cost reductions, are on track to achieve the higher end of their targets, supporting a positive outlook for operating margins. While there are some uncertainties in the US Academic and Government sectors, these account for a small portion of Bruker’s total sales, and the company remains optimistic about its overall growth trajectory. This confidence in future performance and strategic positioning in the market underpins Ryskin’s Buy recommendation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $55.00 price target.